Pfizer’s forward dividend yield stands at approximately 6.8%, substantially above the S&P 500 average of around 1.1%. Management has referred to the payout as a “sacred cow,” underlining its commitment to maintaining distributions. The company’s free cash flow exceeded its dividend payments in the latest fiscal year, with cash from operations of about $21 billion comfortably covering $9 billion in dividends. Investors deploying $12 000 at current yields could expect roughly $820 annually, highlighting Pfizer’s appeal to income-focused portfolios.

After closing its $43 billion acquisition of Seagen in 2023 and its up-to-$10 billion purchase of GLP-1 specialist Metsera in late 2025, Pfizer’s late-stage pipeline now includes obesity candidate MET-097i. Phase 2b data from Vesper-2 and Vesper-3 trials are due in early 2026, and positive outcomes could accelerate entry into a market projected by Grand View Research to reach over $200 billion by 2033. Pfizer also recently inked a licensing deal worth up to $2.1 billion with a Chinese biotech for its early-stage GLP-1 asset, underscoring management’s focus on high-growth therapeutic areas.

For fiscal 2026, Pfizer forecasts revenue between $59.5 billion and $62.5 billion, with the midpoint slightly below its 2025 sales run-rate. Adjusted EPS are projected to fall about 5.7% year-over-year at the midpoint, driven by an expected $1.5 billion decline in COVID-19 product sales and a further $1.5 billion impact from products losing exclusivity. Blockbuster drugs like Eliquis, Ibrance and Xtandi face patent expirations between 2026 and 2027, intensifying the company’s near-term growth challenges.

Pfizer’s shares trade at a forward price-to-earnings ratio near 8.5, well below the healthcare sector average of roughly 15, providing a valuation cushion against execution risks. The company’s market capitalization of about $140 billion reflects investor caution, yet also offers potential upside should pipeline data exceed expectations or cost-saving initiatives deliver more efficiency. For patient investors comfortable with patent cliffs, the combination of high yield and low valuation may justify a long-term allocation.